Mutant V600E BRAF increases hypoxia inducible factor-1α expression in melanoma

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3177-3184

  Kumar, Suresh M ^a   Yu, Hong ^a   Edwards, Robin ^a   Chen, Lianjun ^a   Kazianis, Steven ^b   Brafford, Patricia ^b   Acs, Geza ^a   Herlyn, Meenhard ^b   Xu, Xiaowei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MUTANT PROTEIN; BENZENESULFONIC ACID DERIVATIVE; BRAF PROTEIN, HUMAN; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA FINGERPRINTING; DNA MICROARRAY; DRUG INHIBITION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; MELANOMA; PRIORITY JOURNAL; RNA INTERFERENCE; BIOSYNTHESIS; CELL HYPOXIA; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

BENZENESULFONATES; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 34248193424     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3312     Document Type: Article

References (40)

1. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
2. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
4. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004;10:1753-7.
5. Piepkorn M. The Spitz nevus is melanoma Am J Dermatopathol 2005;27:367-9.
6. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
7. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
8. Aust DE, Haase M, Dobryden L, et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer 2005;115:673-7.
9. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
10. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65:2412-21.
11. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer 2003;2:23.
12. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
13. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298-309.
14. Haddad JJ. Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology. Cytokines Cell Mol Ther 2002;7:1-14.
15. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823-30.
16. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
17. Gardner AM, Vaillancourt RR, Lange-Carter CA Johnson GL. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Mol Biol Cell 1994;5:193-201.
18. Lim JH, Lee ES, You HJ, Lee JW, Park JW, Chun YS. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004;23:9427-31.
19. Chun YS, Lee KH, Choi E, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res 2003;63:8700-7.
20. Galabova-Kovacs G, Matzen D, Piazzolla D, et al. Essential role of B-Raf in ERK activation during extraembryonic development Proc Natl Acad Sci U S A 2006;103:1325-30.
21. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997;16:293-7.
22. Khavari PA. Modelling cancer in human skin tissue. Nat Rev Cancer 2006;6:270-80.
23. Kumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006;16:275-83.
24. Yoo YG, Yeo MG, Kim DK, Park H, Lee MO. Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha. J Biol Chem 2004;279:53365-73.
25. Fukushima T, Takenoshita S. Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci 2005;51:67-75.
26. Trovisco V, Soares P, Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006;37:781-6.
27. Sensi M, Nicolini G, Petti C, et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma Oncogene 2006;25:3357-64.
28. Haluska FG, Ibrahim N. Therapeutic targets in melanoma: MAPKinase pathway. Curr Oncol Rep 2006;8:400-5.
29. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006;16:97-103.
30. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-15.
31. Maxwell PH. Oxygen homeostasis and cancer: insights from a rare disease. Clin Med 2002;2:356-62.
32. Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally down-regulating MutSalpha expression. Mol Cell 2005;17:793-803.
33. Garcia JA. HIFing the brakes: therapeutic opportunities for treatment of human malignancies. Sci STKE 2006;2006:e25.
34. Shi YH, Wang YX, Bingle L, et al. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol 2005;205:530-6.
35. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006;91:3667-70.
36. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004;3:647-54.
37. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003;13:83-9.
38. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003;4:757-63.
39. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;17:578-83.
40. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.